Nfc-1    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
20322q11.2 deletion syndrome1

203. 22q11.2 deletion syndrome    [ 3 clinical trials,   3 drugs,   (DrugBank: 0),   0 drug target gene,   0 drug target pathway]
Searched query = "22q11.2 deletion syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 3 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02895906
(ClinicalTrials.gov)
November 28, 201629/8/2016Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric ConditionsA 5-Week, Multi-center, Open-label Study to Assess the Safety and Efficacy of NFC-1 in Subjects Aged 12-17 Years With 22q11.2 Deletion Syndrome and Commonly Associated Neuropsychiatric Conditions (Anxiety, ADHD, ASD)22q11.2 Deletion SyndromeDrug: NFC-1Aevi Genomic MedicineNULLCompleted12 Years17 YearsAll2Phase 1United States